Items Tagged ‘revlimid’

August 31st, 2016

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes

By

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology. Myelodysplastic syndromes (MDS) refer to a group of diseases in which […]

View full entry

Tags: clinical trial, General Myelodysplastic Syndrome, lenalidomide, MDS, Myelodysplastic Syndrome, News, RBC, revlimid


December 21st, 2015

Addition of Velcade® to Revlimid®/Dexamethasone Improves Survival in Newly Diagnosed Multiple Myeloma

By

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately undergo a stem cell transplant. These results were presented at the 2015 annual meeting of the American Society of Hematology in […]

View full entry

Tags: bortezomib, Multiple Myeloma, News, revlimid, velcade


December 8th, 2014

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma

By

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly diagnosed multiple myeloma, according to the results of a study published in The Lancet Oncology. Multiple myeloma is a cancer of plasma cells. Plasma cells are a special […]

View full entry

Tags: ixazomib, Multiple Myeloma, News, revlimid, Stage I/Smoldering Myeloma Multiple Myeloma, Stages II-III Multiple Myeloma


September 4th, 2014

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL

By

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect of the non–germinal B-cell phenotype in diffuse large B-cell lymphoma which is associated with significantly worse outcomes with […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, revlimid